Ziegler J L, Magrath I T, Olweny C L
Lancet. 1979 Nov 3;2(8149):936-8. doi: 10.1016/s0140-6736(79)92627-8.
192 Ugandan patients with Burkitt's lymphoma were treated with various regimens containing high-dose cyclophosphamide. 21 patients died during induction therapy, and 14 died after partial responses. Of 157 patients who responded completely to treatment, 16 were lost to follow-up (10 in 69 died and 72 (51%) are alive and disease-free. 31 of the long-term survivors have relapsed at least once and have been successfully retreated. Overall, 34 surviving patients had central-nervous-system involvement, also successfully treated. It is concluded that Burkitt's lymphoma is curable in at least 50% of patients, and that relapse and central-nervous-system involvement are not incompatible with long survival.
192名患有伯基特淋巴瘤的乌干达患者接受了包含大剂量环磷酰胺的各种治疗方案。21名患者在诱导治疗期间死亡,14名患者在部分缓解后死亡。在157名对治疗完全缓解的患者中,16名失访(69名中有10名死亡,72名(51%)存活且无疾病。31名长期存活者至少复发过一次并已成功接受再次治疗。总体而言,34名存活患者有中枢神经系统受累,也已成功治疗。结论是,至少50%的伯基特淋巴瘤患者可治愈,且复发和中枢神经系统受累与长期存活并非不相容。